[{"address1": "17 Drydock Avenue", "address2": "Suite #17-401", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "(978) 237-4380", "website": "https://www.aktisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aktis Oncology, Inc. develops and manufactures precision radiopharmaceutical therapies for cancer treatment. The company focuses on solid tumors with limited treatment options, engineering targeted therapies that utilize alpha-emitting particles to deliver cancer-killing effects while minimizing exposure to healthy tissue. It employs a theranostic approach, using imaging tools to visualize and verify tumor targeting, and to predict patient response. The company manages logistics and just-in-time delivery of its radiopharmaceuticals to ensure timely administration. Aktis Oncology serves healthcare providers and medical professionals involved in cancer treatment. The company was founded in 2020 and is based in Boston, Massachusetts.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Todd  Foley M.B.A.", "age": 53, "title": "Co-Founder & Chairman", "yearBorn": 1972, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Roden Ph.D.", "title": "President, CEO & Director", "fiscalYear": 2025, "totalPay": 914680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrick A. Baeuerle Ph.D.", "age": 67, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1958, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kyle D. Kuvalanka", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nate  Demars", "title": "Executive Director & Head of Clinical Operations", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yuan  Xue Ph.D.", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0, "regularMarketPreviousClose": 0.0, "payoutRatio": 0.0, "averageVolume": 3097164, "averageVolume10days": 3097164, "averageDailyVolume10Day": 3097164, "marketCap": 1953828, "fiftyTwoWeekLow": 19.3326, "fiftyTwoWeekHigh": 29.16, "allTimeHigh": 29.16, "allTimeLow": 19.3326, "priceToSalesTrailing12Months": 0.35140792, "fiftyDayAverage": 22.4, "twoHundredDayAverage": 22.4, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": "NaN", "currency": "USD", "tradeable": false, "enterpriseValue": 66508544, "profitMargins": 0.0, "sharesOutstanding": 52522279, "impliedSharesOutstanding": 52522280, "bookValue": -162.432, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -60649000, "trailingEps": -1.16, "enterpriseToRevenue": 11.962, "enterpriseToEbitda": -0.938, "52WeekChange": 0.0, "SandP52WeekChange": 0.18594909, "quoteType": "EQUITY", "currentPrice": 0.0372, "recommendationKey": "none", "totalCash": 297168000, "totalCashPerShare": 364.592, "ebitda": -70869000, "totalDebt": 12010000, "quickRatio": 9.19, "currentRatio": 9.268, "totalRevenue": 5560000, "debtToEquity": 4.89, "revenuePerShare": 7.008, "returnOnAssets": -0.14799, "returnOnEquity": -0.26504, "grossProfits": -58004000, "freeCashflow": -36264000, "operatingCashflow": -61685000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -16.75777, "financialCurrency": "USD", "symbol": "AKTS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "shortName": "Aktis Oncology, Inc. Common stock", "longName": "Aktis Oncology, Inc. Common stock", "marketState": "CLOSED", "twoHundredDayAverageChangePercent": -0.99833924, "priceToBook": -0.0002290189, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "newListingDate": "2026-01-09", "ipoExpectedDate": "2026-01-09", "cryptoTradeable": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1767969000000, "regularMarketChange": 0.0372, "fullExchangeName": "Nasdaq", "averageDailyVolume3Month": 3097164, "fiftyTwoWeekLowChange": -19.295399, "fiftyTwoWeekLowChangePercent": -0.9980757, "fiftyTwoWeekRange": "19.3326 - 29.16", "fiftyTwoWeekHighChange": -29.122799, "fiftyTwoWeekHighChangePercent": -0.9987242, "fiftyTwoWeekChangePercent": 0.0, "epsTrailingTwelveMonths": -1.16, "fiftyDayAverageChange": -22.362799, "fiftyDayAverageChangePercent": -0.99833924, "twoHundredDayAverageChange": -22.362799, "corporateActions": [{"header": "New Listing", "message": "AKTS is newly listed on Nasdaq effective Jan. 9, 2026", "meta": {"eventType": "NEW_LISTING", "dateEpochMs": 1767934800000, "exchange": "Nasdaq"}}], "regularMarketTime": 1764104400, "exchange": "NAS", "messageBoardId": "finmb_708181619", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketPrice": 0.0372, "displayName": "Akoustis", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]